 BOSTON, Oct. 18, 2021 GLOBE NEWSWIRE -- Radius Health, Inc. Radius or the Company NASDAQ: RDUS, today announced positive topline results from the ATOM study evaluating abaloparatide 80mcg subcutaneous SC for use in males with osteoporosis. 